PI Industries reports Q2 FY27 standalone and consolidated results

PI Industries has announced its unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2026. The results were approved by the Board of Directors on November 4, 2026. The standalone financial statements include revenue from operations of ₹15,335 million for the quarter and ₹31,324 million for the half-year. The consolidated results show revenue from operations of ₹17,018 million for the quarter and ₹34,041 million for the half-year.

PI Industries Announces Q2 FY27 Financial Results

PI Industries Limited has officially released its unaudited standalone and consolidated financial results for the second quarter and the first half of the fiscal year 2026-27, ending on September 30, 2026. The financial statements were reviewed by the Audit Committee and subsequently approved by the Board of Directors during their meeting held on November 4, 2026.

Standalone Financial Highlights

For the quarter ended September 30, 2026, PI Industries reported standalone revenue from operations of ₹15,335 million and a profit before tax of ₹2,752 million. For the half-year ended the same date, standalone revenue from operations stood at ₹31,324 million, with a profit before tax of ₹7,122 million.

Consolidated Financial Performance

On a consolidated basis, the company registered revenue from operations of ₹17,018 million for the quarter ended September 30, 2026, with a profit before tax of ₹1,840 million. For the half-year ended September 30, 2026, consolidated revenue from operations was ₹34,041 million, and profit before tax amounted to ₹5,058 million.

Segmental Performance

The consolidated results also provide a breakdown by segment. The ‘Agro chemicals’ segment reported revenue of ₹16,280 million for the quarter and ₹32,768 million for the half-year. The ‘Pharma’ segment reported revenue of ₹759 million for the quarter and ₹1,301 million for the half-year. Segment assets for Agro chemicals were ₹124,244 million and for Pharma were ₹14,414 million as at September 30, 2026.

Source: BSE

Previous Article

Hindustan Unilever reports 15% underlying sales growth in Q2 2026

Next Article

KSH International approves capacity expansion to 72,200 MTs with strong Q2 FY27 results